Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship G7 sensor. The new system, which boosts wear time up from the previous ...

Dexcom has begun to make progress in penetrating the Type 2 market, in addition to long dominating the Type 1 market ... US regulatory approval of the G7 15-day sensor, and the offsetting pressure ...

The company’s shares have lost 5.4% against the industry’s 1.9% growth so far this year. The S&P 500 Index declined 2.7% in the same period. The potential launch of the Dexcom G7 15-day sensor ...

Dexcom reaffirmed its 2025 revenue guidance ... impacted by expedited freight costs and supply chain adjustments following sensor shipment damages last year. Adjusted EBITDA for Q1 was $230.4 ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 ... 1 Dexcom, Data on File, 2025. 2 Dexcom, Data on File, 2023. 3 Garg ...

Credit: Dexcom. The Dexcom G7 15 Day CGM system ... scanning required. The sensor was evaluated in a study that included 130 adults aged 18 years and older with type 1 or type 2 diabetes.

Continuous glucose meters (CGMs) aren’t just widgets for the wellness crowd. For many, CGMs are real-time feedback machines for the body, offering glucose trendlines that help people rethink ...

The FDA has cleared the Dexcom G7 15 Day for adults with type 1 and ... with less sensor changes. The extended wear time of 15 days is similar to the Abbott FreeStyle Libre 2+ and Libre 3 ...

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250410304660/en/ Dexcom G7 15 Day is now cleared in the ...

“The approval of Dexcom G7 15 Day marks another major innovation for Dexcom,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “By listening to the needs of ...